J. Leighton Read

Dr Read is the Executive Chairman at Global Kinetics and Venture Partner at Brandon Capital. He is an American serial entrepreneur and venture investor with a track record of building successful companies across the range of life-science technologies. He was previously a managing director of Alloy Ventures and before that had co-founded Affymax NV (acquired by GSK, was the founding investor, Chairman and CEO of Aviron the company that developed FluMist acquired by MedImmune) and Avidia (acquired by Amgen). Leighton has a Bachelor of Science from Rice University and an MD from the University of Texas Health Science Center. He completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at the Harvard Medical School and School of Public Health publishing in the fields of decision and cost-effectiveness analysis. Leighton is currently a director of EBR Systems, Foundry Therapeutics 1 Okogen and Glyscend. He is also a director of BioVentures for Global Health.